Despite the current volatility in the biotech sector, two stocks stand out as potential long-term investments: Moderna (MRNA) and Regeneron (REGN). Moderna’s innovative mRNA vaccine platform positions it for significant growth, with a pipeline that includes a flu vaccine and a personalized cancer vaccine showing promising results in clinical trials. Although the company has faced revenue declines since 2022, its deep pipeline could lead to substantial returns in the future.

Regeneron also presents a compelling case for investors, primarily due to its strong product lineup, including the blockbuster eczema treatment Dupixent, which continues to expand its market reach. The company is actively developing a range of therapies, including a gene therapy for genetic deafness and a weight-loss drug, which could enhance its growth trajectory. Additionally, Regeneron’s commitment to returning capital through dividends and share buybacks adds to its appeal.

For market professionals, both Moderna and Regeneron offer intriguing opportunities, especially for those looking to invest $2,000 in biotech stocks with the potential for significant long-term returns.

Source: fool.com